Merck’s Thrombin Receptor Antagonist Suffers Major Setback
Merck’s thrombin receptor antagonist, vorapaxar, has suffered a major setback in its clinical trial program. In one trial, TRACER, the study drug is being discontinued and the trial will be closed out....
View ArticleEnd of an Era: Eugene Braunwald Steps Down, Marc Sabatine Assumes Chair of...
Marc Sabatine has replaced Eugene Braunwald as the chairman of the TIMI study group. Braunwald, who has been the dominant figure in cardiology for many decades, is 81. Sabatine was appointed Vice...
View ArticleTicagrelor Improves Outcomes After Myocardial Infarction
For the first time, a very large trial has shown that dual antiplatelet therapy (DAPT) improves cardiovascular outcomes when given to patients 1 to 3 years after a myocardial infarction. Because DAPT...
View Article
More Pages to Explore .....
